Daiwa Securities Group
KYMR icon

Daiwa Securities Group’s Kymera Therapeutics KYMR Stock Holding History

Daiwa Securities Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-215
Closed -$17K – 1325
2025
Q4 		$17K Hold
215
– – ﹤0.01% 1161
2025
Q3 		$12K Sell
215
-30
-12% -$1.35K ﹤0.01% 1149
2025
Q2 		$11K Hold
245
– – ﹤0.01% 1118
2025
Q1 		$7K Hold
245
– – ﹤0.01% 1111
2024
Q4 		$10K Hold
245
– – ﹤0.01% 1121
2024
Q3 		$12K Buy
245
+35
+17% +$1.55K ﹤0.01% 1120
2024
Q2 		$6K Hold
210
– – ﹤0.01% 1190
2024
Q1 		$8K Sell
210
-11
-5% -$394 ﹤0.01% 1178
2023
Q4 		$6K Hold
221
– – ﹤0.01% 1194
2023
Q3 		$3K Hold
221
– – ﹤0.01% 1200
2023
Q2 		$5K Hold
221
– – ﹤0.01% 1180
2023
Q1 		$7K Hold
221
– – ﹤0.01% 1133
2022
Q4 		$6K Buy
221
+71
+47% +$1.89K ﹤0.01% 1142
2022
Q3 		$3K Hold
150
– – ﹤0.01% 1198
2022
Q2 		$3K Hold
150
– – ﹤0.01% 1203
2022
Q1 		$6K Hold
150
– – ﹤0.01% 1159
2021
Q4 		$10K Buy
+150
New +$8.74K ﹤0.01% 1151

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Daiwa Securities Group's KYMR Position: Q1 2026 in Review

Daiwa Securities Group sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 215 shares — an estimated $17K sold.

Daiwa Securities Group first reported a position in KYMR in Q4 2021 and held it in 17 quarters. The position peaked at $17K in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Daiwa Securities Group reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 215 Kymera Therapeutics shares in Q1 2026, an estimated $17K.
  • Daiwa Securities Group first reported a position in Kymera Therapeutics in Q4 2021 and held it in 17 quarters.
  • Daiwa Securities Group's Kymera Therapeutics position peaked at $17K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.